美股异动 | 减肥药板块股票走低 礼来(LLY.US)暴跌超5%

Group 1 - The weight loss drug sector is under pressure, with significant declines in stock prices for major companies [1] - Eli Lilly (LLY.US) experienced a drop of over 5% as its weight loss drug was placed on the FDA review list, with a decision now postponed until April 10, 2026 [1] - Novo Nordisk (NVO.US) fell by more than 4%, while Pfizer (PFE.US) and Amgen (AMGN.US) both saw declines of over 1% [1]